Khare T, Khare S, Ibdah JA. Proteomics approaches for early detection and targeted therapy of hepatocellular carcinoma. World J Gastrointest Oncol 2017; 9(1): 1-3 [PMID: 28144394 DOI: 10.4251/wjgo.v9.i1.1]
Corresponding Author of This Article
Jamal A Ibdah, MD, PhD, Professor, Director, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Missouri-Columbia, 1 University Blvd, Columbia, MO 65212, United States. ibdahj@health.missouri.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Jan 15, 2017; 9(1): 1-3 Published online Jan 15, 2017. doi: 10.4251/wjgo.v9.i1.1
Proteomics approaches for early detection and targeted therapy of hepatocellular carcinoma
Tripti Khare, Sharad Khare, Jamal A Ibdah
Tripti Khare, Sharad Khare, Jamal A Ibdah, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Missouri, Columbia, MO 65212, United States
Sharad Khare, Jamal A Ibdah, Harry S. Truman Memorial Veterans’ Hospital, Columbia, MO 65201, United States
Author contributions: Khare T conceived the topic, reviewed the literature, designed and wrote the manuscript; Khare S edited and provided intellectual input into the design and execution of manuscript; Ibdah JA edited and communicated the manuscript.
Conflict-of-interest statement: The authors declare no conflicts of interest regarding this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jamal A Ibdah, MD, PhD, Professor, Director, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Missouri-Columbia, 1 University Blvd, Columbia, MO 65212, United States. ibdahj@health.missouri.edu
Telephone: +1-573-8827349 Fax: +1-573-8844595
Received: August 8, 2016 Peer-review started: August 10, 2016 First decision: September 12, 2016 Revised: September 28, 2016 Accepted: November 21, 2016 Article in press: November 22, 2016 Published online: January 15, 2017
Abstract
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related mortality worldwide. HCC incidences have increased worldwide though more prevalent in Asia and Africa. Hepatitis B virus and hepatitis C virus infections are mostly responsible of increased number of HCC cases. Biomarkers can help early detection and improve treatment regimen in patients as advanced stage is chemo-refractive with limited treatment options. Potential of proteomics in finding new biomarkers for early detection has been explored more recently. Future developments in this area rely on how efficiently we manage vast amount of data generated by these techniques and speed up the clinical trials to improve patient care.
Core tip: Despite ongoing development in treatment for hepatocellular carcinoma (HCC), effective biomarkers for diagnosis and treatment for HCC are not available. Profiling of proteins puts proteomics on the forefront to understand promising new biomarkers and drug targets for HCC. HCC proteome database would be an important step towards identifying tumor associated proteins as potential therapeutic targets in the treatment of HCC.
